NHF Announces Spring Webinar Lineup
Webinars occur on Wednesdays at 2 p.m. Eastern and are broadcast live
April 1, 2022
New York, NY--The National Hemophilia Foundation (NHF) is pleased to announce its upcoming lineup in the Wednesday Webinars series. The webinars will explore a variety of topics and renowned researchers who will discuss novel research relevant to the inheritable blood and bleeding disorders community.
The below schedule highlights NHF’s upcoming lineup of webinars. (Webinar scheduling is subject to change; please visit hemophilia.org/events for the latest updates).
- April 6: Mark Skinner presents on the effect of emicizumab prophylaxis on long‐term self‐reported physical health in persons with hemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
- April 13: Dr. Brooke Sadler looks at how whole 1 exome analysis of adolescents with low VWF and heavy menstrual bleeding can identify novel genetic associations
- April 20: Dr. Boris Gorovits evaluates the humoral response to the adeno-associated virus-based gene
- April 27: Dr. Kevin Mills provides an update on AAV antibodies
- May 4: Dr. Lindsey George shares on multiyear FVIII expression after AAV gene transfer for hemophilia a
- May 18: Lena Volland, DPT, explores inhibitors
- May 25: The American Thrombosis & Hemostasis Network gives an exclusive look at their new Robust Health app
Webinars are held at 2 p.m. ET and are free and open to the public. Online registration and past-event replays are available at NHF's calendar. Webinars stream live on ZOOM, Facebook, LinkedIn, and YouTube. An audience Q&A session generally begins around 2:45 p.m. ET but questions are welcome to be submitted in advance to communications@hemophilia.org.
NHF created the weekly webinar series in 2020 to educate and inspire throughout the height of the COVID-19 pandemic. Since then, the webinars have continued to serve the inheritable blood and bleeding disorders as an informative and popular weekly event. Click here to view past webinar recordings.